Europe’s CHMP Okays Samsung’s Infliximab Biosimilar
This article was originally published in PharmAsia News
Executive Summary
Samsung Bioepis' infliximab biosimilar, Flixabi, has won a green light from the European Medicines Agency's CHMP for a broad range of indications, marking another step forward for the South Korean firm’s international ambitions.